Abstract 1639P
Background
Endoscopic fine needle biopsy (EUS-FNB) is an effective tissue sampling modality for diagnosing pancreatic cancer. Genomic sequencing is becoming essential with the emerging targeted therapies in pancreatic cancer. However, the feasibility of commercial comprehensive next-generation sequencing on tissue obtained from EUS-FNB is unknown. We aimed to examine the success rate of genomic sequencing utilizing tissue from EUS-FNB and correlate it with procedural characteristics.
Methods
We retrospectively reviewed a consecutive cohort of patients who underwent a diagnostic EUS-FNB during the workup of a pancreatic mass, over five years, at our institution. Genomic results, patient demographics, tumor characteristics, and technical aspects of the EUS-FNB were reviewed. The successful completion of sequencing was defined as the generation and reporting of DNA sequencing results.
Results
A total of 396 patients underwent endoscopic ultrasound with pancreatic mass biopsy as part of the routine diagnostic workup. Tumor sequencing from the pancreatic EUS-FNB was requested from 101 patient samples. The remaining samples had no sequencing performed, or sequencing was requested on pancreatectomy samples and/or metastatic sites. Of the 101 patients, sequencing was successful in 88 samples (87%). The median number of needle passes to obtain sufficient tissue for completion of sequencing was 3 (range 1-5). Tumor purity information was available in 71 samples; the average purity was 32% (range 20-90%). Genomic sequencing was unsuccessful in the remaining 13 samples (13%) due to inadequate tissue. The median number of needle passes for these patients was 2 (range 1-5). The cancer stage distribution for patients whose tumor sequencing was requested from pancreatic biopsies was the following: I (9%), II (10%), III (14%), and IV (67%). Genomic sequencing results will be presented at the meeting.
Conclusions
Comprehensive genomic sequencing of all stages of pancreatic cancer is feasible on EUS-FNB. Increasing the number of needle passes can increase the yield for tumor genomic sequencing. This is particularly important for locally advanced, unresectable pancreatic cancers without alternative sites for tissue sampling.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
V. Florou: Financial Interests, Personal, Advisory Role: Deciphera, Incyte. H.P. Soares: Financial Interests, Personal, Advisory Board: TerSera, Ipsen, AstraZeneca, Novartis, ITM. I. Garrido-Laguna: Financial Interests, Personal, Advisory Role: Sotio, Kanaph, Jazz, OncXerna. All other authors have declared no conflicts of interest.
Resources from the same session
1624P - Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Presenter: Manfred Lutz
Session: Poster session 22
1626P - A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
Presenter: Anna Varghese
Session: Poster session 22
1629P - Modified-FOLFIRINOX-losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase II study
Presenter: Alshaimaa Alhanafy
Session: Poster session 22
1630P - Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
Presenter: Ashwini Cheryl Kanhailal
Session: Poster session 22
1631P - Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)
Presenter: Gabriela Fuentes
Session: Poster session 22
1632P - Organoids as tools for functional precision oncology in advanced pancreatic cancer
Presenter: Alice Boileve
Session: Poster session 22
1633P - Development and clinical validation of news transcriptomic tools for predicting the response to individual drug of the mfolfirinox regimen in patients with pancreatic ductal adenocarcinoma
Presenter: Nicolas Fraunhoffer
Session: Poster session 22